Group 1 - The company Corning Incorporated announced a share buyback of 560,000 shares at a total cost of HKD 5.261 million [1] - The buyback price per share ranged from HKD 9.24 to HKD 9.52 [1]

格隆汇11月7日丨康宁杰瑞制药-B(09966.HK)公告，11月7日耗资526万港元回购56万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康寧傑瑞生物製藥 呈交日期： 2025年11月7日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09966 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康寧傑瑞生物製藥 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 本月底法定/註冊股本總額： USD 50,200 FF301 第 1 頁 共 11 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09966 | 說明 | 普通股 | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | 已發行股份總數 | | | 上月底結存 | | | 971,195,697 | 2,952,000 | | 974,147,697 | | 增加 / 減少 (-) | | | -1,121,000 | 1,121,000 | | | | 本月底結存 | | | 970,0 ...

Summary of Key Points Core Viewpoint - Multiple companies conducted share buybacks on October 28, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent. Group 1: Buyback Details - China Feihe (06186) repurchased 5.174 million shares for a total of 21.6293 million yuan, representing 0.209% of its total share capital [1][2] - Lianyi Rong Technology (09959) repurchased 1.4625 million shares for 4.7622 million yuan, accounting for 3.638% of its total share capital [2] - Zhongxu Future (09890) repurchased 301,400 shares for 4.4130 million yuan, which is 1.270% of its total share capital [2] Group 2: Other Notable Buybacks - Mengniu Dairy (02319) repurchased 300,000 shares for 4.2977 million yuan, representing 0.563% of its total share capital [2] - Jitu Express (01519) repurchased 385,000 shares for 3.8812 million yuan, which is 0.014% of its total share capital [2] - Kangning Jereh Pharmaceutical (09966) repurchased 320,000 shares for 3.7683 million yuan, accounting for 0.117% of its total share capital [2] Group 3: Additional Companies Involved - Other companies involved in the buyback include: - Guichuang Tongqiao-B (02190) with 50,000 shares repurchased for 1.2065 million yuan [2] - Green City Services (02869) with 208,000 shares repurchased for 969,700 yuan [2] - Tianfu (06868) with 2,000 shares repurchased for 60,400 yuan [3]

Core Viewpoint - Corning Incorporated announced a share buyback of 320,000 shares at a total cost of HKD 3.7684 million, with individual share prices ranging from HKD 11.53 to HKD 11.97 [1] Group 1 - The company plans to repurchase shares on October 28, 2025 [1] - The total expenditure for the buyback is approximately HKD 3.7684 million [1] - The price range for the repurchased shares is between HKD 11.53 and HKD 11.97 per share [1]

Core Viewpoint - Corning Pharmaceutical-B (09966.HK) announced a share buyback of 320,000 shares at a cost of HKD 3.768 million on October 28 [1] Group 1 - The company executed a buyback program, indicating a strategy to enhance shareholder value [1] - The total expenditure for the buyback was HKD 3.768 million, reflecting the company's commitment to returning capital to shareholders [1] - The number of shares repurchased was 320,000, which may influence the stock's liquidity and market perception [1]

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Categories Company Actions - The company plans to repurchase 320,000 shares at a total cost of HKD 3.7684 million [1] - The buyback price per share ranges from HKD 11.53 to HKD 11.97 [1] Financial Implications - The total expenditure for the buyback reflects the company's strategy to enhance shareholder value [1]

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09966 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年10月16日 ...

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) announced that JSKN003 has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, marking a significant milestone in the global development of JSKN003 [1] Group 1 - JSKN003 has been granted FTD by the FDA for treating platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, indicating its clinical potential [1] - The FDA has also approved a Phase II clinical trial for JSKN003 targeting platinum-resistant recurrent epithelial ovarian cancer with no restrictions on HER2 expression levels [1] - JSKN003 has received breakthrough therapy designation from the National Medical Products Administration (NMPA) for both PROC and colorectal cancer (CRC), and orphan drug designation from the FDA for gastric/gastroesophageal junction cancer (GC/GEJ) [1] Group 2 - The Phase III clinical trial for JSKN003 in treating platinum-resistant recurrent epithelial ovarian cancer is currently progressing smoothly in China [1] - The FTD designation further underscores the confidence of international regulatory bodies in the clinical potential and importance of JSKN003 as a novel therapeutic candidate [1]